SCHEMBL6435806

SCHEMBL6435806

CNC(=O)[C@@H](NC(=O)C(CC(C)C)[C@@H](O)C(N)=O)C(C)(C)C

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 11/20 0.75
ADAM17 P78536 11/20 0.75
MMP3 P08254 9/20 0.75
MMP2 P08253 7/20 0.75
MMP9 P14780 7/20 0.75
MMP8 P22894 5/20 0.75
MMP7 P09237 3/20 0.75
MMP13 P45452 3/20 0.75
TNF P01375 2/20 0.75
MMP20 O60882 1/20 0.75
ADAMTS4 O75173 1/20 0.75
MMP10 P09238 1/20 0.75
MMP12 P39900 1/20 0.75
MMP14 P50281 1/20 0.75
MMP15 P51511 1/20 0.75
MMP16 P51512 1/20 0.75
MMP25 Q9NPA2 1/20 0.75
MMP26 Q9NRE1 1/20 0.75
ADAMTS5 Q9UNA0 1/20 0.75
MMP24 Q9Y5R2 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9714274 1.00 MMP1 (0.75) MMP1ADAM17MMP3MMP2MMP9
SCHEMBL8026827 0.87 ADAM17 (0.77) MMP1ADAM17MMP3MMP2MMP9
Marimastat SCHEMBL34033 0.86 ADAM17 (1.00) MMP1ADAM17MMP3MMP2MMP9
Marimastat SCHEMBL20793036 0.86 ADAM17 (1.00) MMP1ADAM17MMP3MMP2MMP9
Marimastat SCHEMBL134999 0.86 ADAM17 (1.00) MMP1ADAM17MMP3MMP2MMP9
Marimastat SCHEMBL8193003 0.86 ADAM17 (1.00) MMP1ADAM17MMP3MMP2MMP9
Marimastat SCHEMBL17799241 0.86 ADAM17 (1.00) MMP1ADAM17MMP3MMP2MMP9
Marimastat SCHEMBL8189167 0.86 ADAM17 (1.00) MMP1ADAM17MMP3MMP2MMP9
Marimastat SCHEMBL13253251 0.86 ADAM17 (1.00) MMP1ADAM17MMP3MMP2MMP9
Marimastat SCHEMBL1821430 0.86 ADAM17 (1.00) MMP1ADAM17MMP3MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050020607-A1 Statin-MMP inhibitor combinations NEWTON ROGER SCHOFIELD (US) 2005-01-27 US disclosed
EP-1047450-B1 ACE INHIBITOR-MMP INHIBITOR COMBINATIONS WARNER LAMBERT CO (US) 2002-10-02 EP disclosed
US-20020049237-A1 Statin-MMP inhibitor combinations NEWTON ROGER SCHOFIELD (US) 2002-04-25 US disclosed
US-6340709-B1 ADMINISTERING BIPHENYLSULFONAMIDE DERIVATIVE WARNER-LAMBERT COMPANY 2002-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020607-A1 Statin-MMP inhibitor combinations MMP9, TIMP3, MMP3 MMP1 20/4885ADAM17 31/4885MMP3 3/4885
US-20020049237-A1 Statin-MMP inhibitor combinations MMP9, TIMP3, MMP3 MMP1 20/4885ADAM17 31/4885MMP3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.